Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
desktop iconMarkt Monitor

Koffiekamer« Terug naar discussie overzicht

Nanobiotix met haar NBTXR3 richting €80,- in 2014 ? (Heden €17,-)

524 Posts
Pagina: «« 1 ... 16 17 18 19 20 ... 27 »» | Laatste | Omlaag ↓
  1. [verwijderd] 27 juni 2014 20:02
    This NanoXray technology has begun clinical testing in patients with advanced soft tissue sarcoma, with promising results reported at the American Society of Clinical Oncology meeting earlier this month. More extensive trials will follow soon.
    The aim is to hit the tumour with enough radiation to shrink it to a size where it can be cut out safely without leaving cancer cells behind
  2. [verwijderd] 11 juli 2014 09:23
    Nanobiotix revenues steady; investors focus on a breakthrough year to date

    Nanobiotix (EPA:NANO), which is developing a significant advance on traditional radiotherapy, said revenues for the quarter were €48,596 – exactly the same as the comparable period last year.
    The majority of the income came in an upfront payment from its tie-up with Taiwan-based PharmaEngine. The Euronext-listed technology and healthcare group posted revenues of €93,939 for the first half of 2014.
    Financial performance is very much a secondary consideration at this stage in the development of Nanobiotix.
    The year to date has been one of incredible progress and reflected in a 200% rise in the share price.
    The group has revealed some fairly compelling data that points to the potential of its nano-medicine in cancer patients.
    And it has landed the funding required to see the research group through to regulatory approval here in Europe in 2016.
    The landmark for many followers was the presentation earlier this month to the prestigious American Society of Clinical Oncology conference, the world's largest gathering of cancer doctors.
    Nanobiotix’s data revealed its researchers treated 20 patients with soft tissue sarcoma, which is a cancer that affects muscle, fat and blood vessels.
    Using its very targeted approach to cancer treatment, an injection of the company’s NBTXR3 nano-particles was made direct into the tumour. This was then followed by standard radio-therapy.
    As is the norm with a phase I study, the idea is to test for safety and tolerability rather than efficacy.
    However, Nanobiotix did observe “promising signs of anti-tumour activity”.
    The average tumour shrinkage was 49% with four to five patients experiencing greater than 40% shrinkage.
    Importantly, all patients were able to have their previously inoperable tumours surgically removed.
    Nanobiotix’s technology is elegantly simple in concept. Tiny particles of hafnium oxide are injected directly to the tumour, given intravenously or applied as a gel during surgery to give a targeted treatment.
    This non-toxic material is there to absorb x-rays as well as enhance the dose of radiotherapy. It increases the dose in the tumour without increasing the dose in healthy tissues.
    It is important to stress, while the NanoXray can be administered like a medicine and its particles are so tiny thousands can fit around the circumference of a hair, the reaction is physical rather than chemical or biological.
    What does this mean? Well, it creates a one-size-fits-all approach to treatment that you just don’t have with conventional medicine.
    The next step for Nanobiotix is to initiate a pivotal study for NBTXR3 in patients with advanced soft tissue sarcomas and it expects to start enrolling patients by the end of the year.
    In the interim there are some significant milestones coming up over the next six months, including intermediate results from a head and neck cancer study.
    At the same time it expects to receive feedback from Taiwan’s PharmaEngine, its partner in Asia.
    And then there is the small matter of the US, a huge potential market for the company’s nano-technology.
    The group is still at the “discussion level” with established oncology players, although there are “potential financial partners” that may help fund a launch in America
    In its latest update, research firm Edison said the group, which had €3.9mln at the end of 2013, is well funded following a €28mln cash call last month.
    This is enough to see it through to CE Mark approval in 2016.
    As Nanobiotix technology is classed as a clinical device – because it relies on a physical action rather than chemical and biological interactions with the body – it doesn’t have to proceed up the often tortuous and very expensive clinical trial route.
    In the wake of the recent updates, Edision has raised its net present value for Nanobiotix to €321mln, which means the shares would have to rise a further 34% to achieve this target.
    Broker Oriel Securities sees the fair value of the stock, currently trading at around €15, being closer to €22.
  3. [verwijderd] 11 juli 2014 09:24
    Nanobiotix revenue for the 2nd quarter of 2014

    NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the second quarter of 2014.

    Income statement


    In € Q2 2014 H1 2014 Q2 2013
    Revenues 48,596 93,939 48,569

    Of which :


    License
    Services


    45,847
    2,749


    91,190
    2,749


    45,847
    2,722

    Activity

    The revenue recorded by NANOBIOTIX during the second quarter of 2014 relates to the upfront payment (pro-rata share) from the Taiwan-based PharmaEngine within the framework of the licensing contract. This licensing contract was signed in August 2012 for the development and commercialization of Nanobiotix’s lead product, NBTXR3 in the Asia-Pacific region. It is distributed using the straight-line method across the period between the date the contract was signed and the scheduled marketing launch in the region. This upfront payment totaled €810,640, generating a product of €45,847 for the period and totalling €91,190 for the first semester in 2014. The invoicing of services totalled €2,749 for the second quarter of 2014. In total, revenue for the second quarter amounts €48,596. Revenue for the first half of 2014 is €93,939 which is fully in line with Company expectations.

    During Q2, Nanobiotix presented successful Phase I results for its lead product NBTXR3 at the American Society of Clinical Oncology (ASCO). Final results demonstrated very good safety, treatment feasibility and promising signs of efficacy in patients with advanced Soft Tissue Sarcomas. These results allow Nanobiotix to proceed to the pivotal phase, which is the final step leading to registration (CE mark), and is planned to commence in Q4 2014.

    Next financial press release: results for the first half of 2014 to be released on August 29, 2014

    ???
  4. [verwijderd] 15 juli 2014 09:40
    French tech star performer Nanobiotix secures funding to fight cancer

    This week we cast our net a little wider than normal to look at one of France’s star performing technology stocks. The year to date has been one of incredible progress for Euronext-listed Nanobiotix with the advances reflected in a share price that has appreciated 200 per cent in that short time. The group, whose technology promises a major advancement on traditional radiotherapy, revealed some fairly compelling data that points to the potential of its nano-medicine in cancer patients.

    The landmark for many followers was the presentation last month to the prestigious American Society of Clinical Oncology (ASCO) conference, the world's largest gathering of cancer doctors. Nanobiotix’s data revealed its researchers treated 20 patients with soft tissue sarcoma, which is a cancer that affects muscle, fat and blood vessels. Using its targeted approach to cancer treatment, an injection of the company’s NBTXR3 nano-particles was made directly into the tumour. This was then followed by standard radiotherapy. As is the norm with a phase I study, the idea is to test for safety and tolerability rather than efficacy.
    However, Nanobiotix did observe 'promising signs of antitumor activity'. The average tumour shrinkage was 49 per cent with four to five patients experiencing greater than 40 per cent shrinkage. Importantly, all patients were able to have their previously inoperable tumours surgically removed. 'We had very good feedback from ASCO. We showed the proof of concept in a clinical study, which was very good for us,' said chief financial officer Philippe Mauberna. Nanobiotix’s technology is elegantly simple in concept. Tiny particles of hafnium oxide are injected directly to the tumour, given intravenously or applied as a gel during surgery to give a targeted treatment. This non-toxic material is there to absorb x-rays as well as enhance the dose of radiotherapy. It increases the dose in the tumour without increasing the dose in healthy tissues.

    It is important to stress, while the liquid can be administered like a medicine and its particles are so tiny thousands can fit around the circumference of a hair, the reaction is physical rather than chemical or biological.
    What does this mean? Well, it creates a one-size-fits-all approach to treatment that you just don’t have with conventional medicine. The next step for Nanobiotix is to initiate a pivotal study for NBTXR3 in patients with advanced soft tissue sarcomas and it expects to start enrolling patients by the end of the year.
    In the interim there are some significant milestones coming up over the next six months, including intermediate results from a head and neck cancer study. At the same time it expects to receive feedback from Taiwan’s PharmaEngine, its partner in Asia.
    And then there is the small matter of the US, a huge potential market for the company’s nano-technology.
    The group is still at the 'discussion level' with established oncology players, although there are 'potential financial partners' that may help fund a launch in America, said Mauberna. 'It is a big market for us. In oncology it is one of the major markets,' he told Proactive Investors, 'We have to be there as a global player with our new technology. 'The cost of entry is much smaller than it would be for biological products.' The firm is well funded following a €28 million cash-raising in May, which is enough to see it through to getting its CE Mark (regulatory approval) in 2016. As Nanobiotix technology is classed as a clinical device – because it relies on a physical action rather than chemical and biological interactions with the body – it doesn’t have to proceed up the often tortuous and very expensive clinical trial route. In the wake of the recent updates, City research firm Edision raised its net present value for Nanobiotix to €321million, which means the shares would have to rise a further 50 per cent to achieve this target. Broker Oriel Securities sees the fair value of the stock, currently trading at around €16, being closer to €22.

    NANOBIOTIX AT A GLANCE
    Ticker: NANO
    Value: €215million
    Current share price: €16.19
    Year high: €33.12
    Low: €5

    www.dailymail.co.uk/money/investing/a...

524 Posts
Pagina: «« 1 ... 16 17 18 19 20 ... 27 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.